Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
BioNano Genomics ( (BNGO) ) has provided an update.
Bionano Genomics has amended its senior secured convertible debentures, enhancing its financial flexibility by deferring principal payments and reducing near-term cash needs. This restructuring is expected to strengthen the company’s capital structure and liquidity position, supporting its operational goals and long-term shareholder value.
More about BioNano Genomics
Bionano Genomics is a provider of genome analysis solutions aimed at transforming genome research and diagnostics. The company offers optical genome mapping solutions, diagnostic services, and software for various research applications, alongside nucleic acid extraction and purification technologies.
YTD Price Performance: -1.92%
Average Trading Volume: 4,451,485
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $26.04M
See more insights into BNGO stock on TipRanks’ Stock Analysis page.
